SynthesisThe journal of headache and pain2020
European Headache Federation recommendations for neurologists managing giant cell arteritis.
Synthesis in The journal of headache and pain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 61 citations in OpenAlex.
- A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.Arthritis research & therapy · 2023Trial
- Recurrent ischemic strokes with normal inflammatory markers: when tests mislead.Acta neurologica Belgica · 2026Article
- Hallmarks of headache disorders: part 5 - secondary headaches.The journal of headache and pain · 2026Review
- Hallmarks of primary headache: part 4 - rare headache syndromes.The journal of headache and pain · 2025Review
- Designing a workshop for a temporal artery biopsy simulation.Digital journal of ophthalmology : DJO · 2025Article
- Updates in the Management of Giant Cell Arteritis.Current neurology and neuroscience reports · 2024Review
- The spectrum of giant cell arteritis through a rheumatology lens.Eye (London, England) · 2024Review
- The changing landscape of thyroid eye disease: current clinical advances and future outlook.Eye (London, England) · 2024Review
- Diagnosing vasculitis with ultrasound: findings and pitfalls.Therapeutic advances in musculoskeletal disease · 2024Review
- The first giant cell arteritis hospital quality standards (GHOST).Eye (London, England) · 2024Article
- Secondary headaches - red and green flags and their significance for diagnostics.eNeurologicalSci · 2023Review
- Giant cell arteritis: reviewing the advancing diagnostics and management.Eye (London, England) · 2023Review
- Giant Cell Arteritis Presenting With Multiple Cranial Neuropathies - Case Report.The Neurohospitalist · 2023Article
- Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?Frontiers in neurology · 2023Article
- Giant Cell Arteritis: A Case-Based Narrative Review of the Literature.Current pain and headache reports · 2022Review
- An update on the clinical approach to giant cell arteritis.Clinical medicine (London, England) · 2022Article
- Editorial: Neurosurgical treatment for neuro-ophthalmologic conditions: Intracranial pressure disorders.Frontiers in ophthalmology · 2022Article
- Current Perspective on Retinal Migraine.Vision (Basel, Switzerland) · 2021Review
- Headache for ophthalmologists: current advances in headache understanding and management.Eye (London, England) · 2021Review
- A Diagnostic Algorithm Based on a Simple Clinical Prediction Rule for the Diagnosis of Cranial Giant Cell Arteritis.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimGiant cell arteritis (GCA) remains a medical emergency because of the risk of sudden irreversible sight loss and rarely stroke along with other complications. Because headache is one of the cardinal symptoms of cranial GCA, neurologists need to be up to date with the advances in investigation and management of this condition. The aim of this document by the European Headache Federation (EHF) is to provide an evidence-based and expert-based recommendations on GCA.
methodsThe working group identified relevant questions, performed systematic literature review and assessed the quality of available evidence, and wrote recommendations. Where there was not a high level of evidence, the multidisciplinary (neurology, ophthalmology and rheumatology) group recommended best practice based on their clinical experience.
resultsAcross Europe, fast track pathways and the utility of advanced imaging techniques are helping to reduce diagnostic delay and uncertainty, with improved clinical outcomes for patients. GCA is treated with high dose glucocorticoids (GC) as a first line agent however long-term GC toxicity is one of the key concerns for clinicians and patients. The first phase 2 and phase 3 randomised controlled trials of Tocilizumab, an IL-6 receptor antagonist, have been published. It is now been approved as the first ever licensed drug to be used in GCA.
conclusionThe present article will outline recent advances made in the diagnosis and management of GCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.